Market revenue in 2023 | USD 5.5 million |
Market revenue in 2030 | USD 18.8 million |
Growth rate | 19.1% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60% in 2023. Horizon Databook has segmented the Mexico plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Growing popularity of gene therapy, rising investments by the government, and rapid growth of biopharmaceutical industry in the country are the primary factors driving growth of the market. However, pharmaceutical & research companies are not encouraged to settle and invest in Mexico, and stringent regulations hinder the growth of the market.
Growth and innovation in the industry are priorities for the Mexican government. In particular, it has enhanced the legal & regulatory frameworks for investment firms, drug manufacturers, healthcare professionals, and patients.
As key drivers of the country's biotechnology innovation, biotech clusters, are starting to emerge in a majority of Mexican states. Moreover, Mexico has the potential to become an emerging market leader in biopharmaceutical innovation.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Mexico plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account